Pharmaceutical

Verekitug by Upstream Bio for Rhinosinusitis: Likelihood of Approval

Verekitug is under clinical development by Upstream Bio and currently in Phase II for Rhinosinusitis.

Feb 8, 2024 - 18:00
Verekitug is under clinical development by Upstream Bio and currently in Phase II for Rhinosinusitis.
Read the original article

Tags:

Previous Article

Tapotoclax by Amgen for Myelodysplastic Syndrome: Likelihood of Approval

Next Article

J&J’s Autoimmune Drug Prospect Meets Phase 3 Goal, Inches Closer to Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

BioAge secures $170m for obesity therapeutics development

BioAge secures $170m for obesity therapeutics development

Feb 14, 2024

MC-232 by MC2 Therapeutics for Hidradenitis Suppurativa...

Oct 3, 2023

STAT+: The biggest health care deals of 2023

STAT+: The biggest health care deals of 2023

Dec 17, 2023